TrialThe oncologist2020

KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer.

Yuxiang Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.